Of the President Emergency plan for AIDS Relief will need a significant contribution to the fight against the HIV / AIDS pandemic, but strengthen strengthen its prevention and develop programs to long term sustainability long-term sustainability in focus countries, according to a report Friday by the Institute of Medicine and the National Research Council, the Washington Post reports for fiscal year 2007 that. One $ 1 click here .3 billion rise in the international HIV / AIDS and tuberculosis programs The resolution brings the total for PEPFAR in 2007 to $ 4, (Kaiser Daily HIV / AIDS Report, for the present report, the IOM panel hundreds of interviews people and sent delegations to 13 of the 15 PEPFAR focus countries. The panel did not open as compared to the PEPFAR model of foreign aid to other models. Addition Furthermore, because the test was soon after many PEPFAR started started the review focused implementation as long-term results. After the IOM report, PEPFAR through September 2006 antiretroviral drugs purchased for 822,000 people in the program the focus countries. Of get treatment access during this period were 61 percent women and 9 percent were children, about 100,000ound. PEPFAR also pays for 165,000 people antiretroviral drugs in other developing countries, according to the report. PEPFAR money was used, 000 pregnant women with access to short courses of treatment to prevent vertical HIV transmission offer. According to program officials, this strategy about 100,000 new cases of HIV infection prevented. In addition, PEPFAR helps support 4.7 million people from families affected by HIV / AIDS, including two million orphans, the Post reports (Washington Post.
Stuart W. President and Chief Executive Officer of PTC Therapeutics, said::. ‘In addition to clinical proof-of-concept data that we announced late last year, these new findings are further evidence supporting the potential of PTC124 in genetic disorders due to a nonsense mutation results in the DMD studies are consistent with the results in phase 2 clinical trials of PTC124 in patients with cystic fibrosis and with preclinical results in the DMD mouse model published recently observed in Nature. We are eager to test this approach to other nonsense genetic disorders genetic disorders expand. ‘. Continue reading